FDA clears Akebia’s drug to treat anaemia in acute kidney disease
HQ Team March 28, 2024: Akebia Therapeutics, a US Massachusetts-based biotechnology company, has got the regulator’s approval for its Vafseo drug to treat anaemia.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team March 28, 2024: Akebia Therapeutics, a US Massachusetts-based biotechnology company, has got the regulator’s approval for its Vafseo drug to treat anaemia.
GSK Plc., a British global pharmaceutical company, announced the FDA had approved an oral drug to treat anaemia arising from chronic kidney disease.